Interim Effectiveness of 2025–2026 mRNA-1283 and BNT162b2 COVID-19 Vaccines Against COVID-19-Related Outcomes Among Adults Aged ≥ 65 Years in the United States
Nevena Vicic, Alina Bogdanov, Heather Hensler, Taylor Ryan, Ni Zeng, Ekkehard Beck, Emily Patry, Machaon Bonafede, Andre B. Araujo, Amanda Wilson · 2026
Read Interim Effectiveness of 2025–2026 mRNA-1283 and BNT162b2 COVID-19 Vaccines Against COVID-19-Related Outcomes Among Adults Aged ≥ 65 Years in the United States by Nevena Vicic, Alina Bogdanov, Heather Hensler, Taylor Ryan, Ni Zeng, Ekkehard Beck, Emily Patry, Machaon Bonafede, Andre B. Araujo, Amanda Wilson (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13476419.txt.
Description
Nevena Vicic and co-authors give early real-world results in 2026 for two updated COVID vaccines in older United States adults. Records linked clinic and billing data through January 2026. Each vaccine group was matched to unvaccinated peers, with weighting to balance traits. Protection against hospital stay and any medical visit for COVID was estimated.
One vaccine, mRNA-1283, drew more than two hundred thirty thousand recipients, while the other drew more than four hundred twenty thousand. Protection against hospital stay sat near fifty-nine percent for the first and forty-eight percent for the second. Protection held up in those aged seventy-five and above. Early data support both shots for older adults.
Catalog record
| CREATOR | Nevena Vicic, Alina Bogdanov, Heather Hensler, Taylor Ryan, Ni Zeng, Ekkehard Beck, Emily Patry, Machaon Bonafede, Andre B. Araujo, Amanda Wilson |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34446 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |